As in the first efficacy study, 75-mg/kg/day of MY-24 had only a subtle protective effect primarily manifested as a delay in mean day of death (10.6±2.3 days compared to 8.9±1.3 days for the placebo: P<0.01) and significantly reduced liver disease as measured by systemic ALT concentrations (333±124 IU/ml compared to 1295±483 IU/ml for the placebo: P<0.001). The gene discussed is GPT; the disease is liver disorder.